- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02168114
Magnetic Resonance and Optical Imaging of Dystrophic and Damaged Muscle
Optical Imaging of Dystrophic and Damaged Muscle
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The overall objective of this proposal is to validate the potential of Optical Imaging techniques to be able to detect and quantify muscle damage in a population affected by Duchenne Muscular Dystrophy, a muscle wasting disease, and in a healthy population that has undergone temporal muscle damage resulting from an exercising intervention.
Duchenne Muscular Dystrophy is a relentlessly progressive degenerative muscle wasting disease, clinically characterized by progressive muscle weakness, a loss of ambulation, and premature mortality. Currently, no known cure exists and treatments that benefit patients diagnosed with Duchenne Muscular Dystrophy are limited. New approaches, such as cell therapy, gene transfer, and pharmacological interventions have shown promising results in animal models and human studies with great potential to develop as effective therapeutic treatments. One of the major limitations of testing these interventions; however. is the lack of effective methods to monitor cellular and tissue changes taking place in the response to therapy. The ability to determine cellular and tissue specific changes in damaged muscles in real time, non-invasively, repeatedly, without exposure to any harmful radiations, with minimal patient discomfort, and at low operating cost would enable high throughput and faster investigation of potential therapies.
The proposed study focuses on the development of Optical Imaging technologies in the near infrared range of wavelengths to differentiate damaged from normal muscle tissue. Near infrared light (700 - 900 nm) has demonstrated the ability to deeply penetrate through biological tissue, skin, and muscle without appreciable attenuation or auto-fluorescence.
The investigators anticipate that Indocyanine Green enhanced Optical Imaging can be used to image exercise induced acute muscle damage in healthy individuals and damaged muscle and in boys with Duchenne Muscular Dystrophy. It is anticipated that this work may fulfill the need for imaging biomarkers that monitor and quantify cellular damage, muscle perfusion, and drug delivery - non-invasively, using benign light, repeatedly, and in real time, with the intention of accelerating the testing of efficacy in clinical trials for neuromuscular disorders. The study is designed to determine the ability of Optical Imaging as a reliable, safe, relatively inexpensive, and facile tool to detect and quantify muscle damage. Investigators anticipate that this type of imaging modality will provide clinically useful information for diagnostic and prognostic purposes in patients with neuromuscular diseases, especially boys with Duchenne Muscular Dystrophy.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32611
- University of Florida
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria for Duchenne Muscular Dystrophy subjects:
- Diagnosis of Duchenne muscular dystrophy confirmed by 1) clinical history with features before the age of 5 years, 2) physical examination, 3) elevated serum creatine kinase level, and 4) absence of dystrophin expression as determined by immune stain or Wester blot (<2%) and/or DNA confirmation of dystrophin mutation
- Must be between 10-15 years of age.
- Must be male.
Inclusion Criteria for unaffected subjects:
- Must be older than 18 years of age.
- Must be male.
Exclusion Criteria for unaffected and Duchenne Muscular Dystrophy subjects:
- Contraindication to an Magnetic Resonance examination (e.g. aneurysm clip, severe claustrophobia, magnetic implants)
- Presence of a condition in patients that impacts muscle function or muscle metabolism (e.g. myasthenia gravis, endocrine disorder, mitochondrial disease)
- Medical condition leading to developmental delay or impaired motor control (e.g. cerebral palsy)
- Unstable medical condition (e.g. uncontrolled seizure disorder)
- Behavioral problems causing an inability to cooperate during testing
- Control subjects who are participating in sport specific training 2 times or more per week
- History of allergy to iodides
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Duchenne Muscular Dystrophy
This arm will only include subjects that have a confirmed diagnosis of Duchenne Muscular Dystrophy.
Subjects in this arm will not undergo any exercising, and will only be imaged by Optical and Magnetic Resonance Imaging and Spectroscopy techniques at a single time point.
|
This arm will contain subjects that are not affected by Duchenne Muscular Dystrophy.
These subjects will undergo concentric exercising of one forearm, and eccentric exercising of the contralateral forearm.
Two days following the exercising, subjects will undergo Optical Imaging and Magnetic Resonance Imaging and Spectroscopy.
|
EXPERIMENTAL: Non-affected Subjects
This arm will contain subjects that are not affected by Duchenne Muscular Dystrophy.
These subjects will undergo concentric exercising of one forearm, and eccentric exercising of the contralateral forearm.
Two days following the exercising, subjects will undergo Optical Imaging and Magnetic Resonance Imaging and Spectroscopy.
|
This arm will contain subjects that are not affected by Duchenne Muscular Dystrophy.
These subjects will undergo concentric exercising of one forearm, and eccentric exercising of the contralateral forearm.
Two days following the exercising, subjects will undergo Optical Imaging and Magnetic Resonance Imaging and Spectroscopy.
This arm will only include subjects that have a confirmed diagnosis of Duchenne Muscular Dystrophy.
Subjects in this arm will not undergo any exercising, and will only be imaged by Optical and Magnetic Resonance Imaging and Spectroscopy techniques at a single time point.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Indocyanine Green accumulation in forearm muscles
Time Frame: Up to 2 days
|
Percentage of area with elevated Indocyanine Green in muscle will be an indicator of cell membrane damage and will be measured using Optical Imaging in the forearms of study participants.
|
Up to 2 days
|
Muscle T2 elevation in forearm muscles
Time Frame: Up to 2 days
|
Muscle T2 is a noninvasive marker of muscle damage/inflammation and will be measured using Magnetic Resonance in the forearms of participants of this study.
|
Up to 2 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Delayed Onset of Muscle Soreness (DOMS)
Time Frame: Up to 2 days
|
DOMS will be correlated to percentage of elevated pixels within forearms of study participants.
|
Up to 2 days
|
Serum Creatine Kinase
Time Frame: Up to 2 days
|
Serum Creatine Kinase is a marker of muscle damage and will be correlated to percentage of elevated pixels within forearms of study participants
|
Up to 2 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Glenn A Walter, Ph.D., University of Florida
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB201602354
- MD110050 (OTHER: Department of Defense)
- 536-2012 (OTHER: UF legacy study)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Duchenne Muscular Dystrophy
-
Cairo UniversityCompletedMuscular Dystrophy, Duchenne TypeEgypt
-
Medical University of GdanskRecruitingDuchenne Muscular Dystrophy (DMD)Poland
-
ItalfarmacoCompletedDuchenne Muscular Dystrophy (DMD)Italy
-
Santhera PharmaceuticalsTerminatedDuchenne Muscular Dystrophy (DMD)United States, Spain, Netherlands, Sweden, Germany, France, Belgium, United Kingdom, Italy, Ireland, Switzerland, Austria, Bulgaria, Hungary, Israel
-
Sarepta Therapeutics, Inc.CompletedDuchenne Muscular Dystrophy (DMD)United States
-
Hospital RudolfstiftungOesterreichische MuskelforschungCompletedCarrier of Duchenne Muscular DystrophyAustria
-
General Hospital of Chinese Armed Police ForcesUnknownDuchenne Muscular Dystrophy (DMD)China
-
Chaitanya Hospital, PuneUnknownMuscular Dystrophy | Duchenne Muscular Dystrophy,India
-
Peking Union Medical College HospitalNot yet recruitingDuchenne Muscular Dystrophy (DMD)
-
University of FloridaU.S. Army Medical Research and Development CommandRecruitingDuchenne Muscular Dystrophy (DMD)United States
Clinical Trials on Optical and Magnetic Resonance Imaging and Spectroscopy
-
OHSU Knight Cancer InstituteUnited States Department of Defense; Oregon Health and Science University; Portland...Completed
-
Centre Hospitalier Universitaire DijonCompleted
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingDiabetes Mellitus, Type 2United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Completed
-
University of California, IrvineBeckman Laser Institute University of California IrvineCompleted
-
Assistance Publique Hopitaux De MarseilleUnknown
-
M.D. Anderson Cancer CenterTerminatedProstate CancerUnited States
-
University of California, IrvineBeckman Laser Institute University of California IrvineCompletedHypoxia-Ischemia, Brain | Signs and SymptomsUnited States
-
University of California, IrvineBeckman Laser Institute University of California IrvineCompletedAccessory; Breast TissueUnited States